Comparative Pharmacology
Head-to-head clinical analysis: FULVICIN P G 330 versus SPORANOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FULVICIN P G 330 versus SPORANOX.
FULVICIN P/G 330 vs SPORANOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fulvicin P/G 330 contains griseofulvin, which inhibits fungal cell mitosis by disrupting the microtubule function, binding to tubulin and preventing assembly of spindle fibers during metaphase.
Inhibits fungal cytochrome P450 (CYP450)-dependent lanosterol 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
330 mg orally once daily with fatty meal to enhance absorption.
200 mg orally twice daily for 3-7 days; for onychomycosis: 200 mg orally once daily for 12 weeks.
None Documented
None Documented
Terminal half-life approximately 9-22 hours in adults, with a mean of ~13 hours. Clinical context: steady-state achieved in 2-3 days; may guide dosing interval.
The terminal elimination half-life of itraconazole ranges from 21 to 35 hours for single doses, increasing to approximately 34 to 42 hours at steady state. The half-life of the active metabolite, hydroxyitraconazole, is similar. This long half-life allows for once-daily or twice-daily dosing in most indications.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal excretion of metabolites: ~36% in feces, ~13% in urine.
Itraconazole is extensively metabolized in the liver via CYP3A4 to active metabolites, including hydroxyitraconazole. The parent drug and metabolites are primarily excreted in feces (approximately 54%) and urine (approximately 35%), with less than 1% of the dose excreted unchanged in urine.
Category C
Category C
Antifungal
Antifungal